Canada Markets closed
  • S&P/TSX

    21,637.54
    -15.48 (-0.07%)
     
  • S&P 500

    4,704.54
    +15.87 (+0.34%)
     
  • DOW

    35,870.95
    -60.10 (-0.17%)
     
  • CAD/USD

    0.7936
    -0.0001 (-0.0095%)
     
  • BTC-CAD

    69,304.23
    -830.48 (-1.18%)
     
  • CMC Crypto 200

    1,402.14
    -65.80 (-4.48%)
     
  • GOLD FUTURES

    1,861.20
    -0.20 (-0.01%)
     
  • RUSSELL 2000

    2,363.59
    -13.42 (-0.56%)
     
  • 10-Yr Bond

    1.5890
    -0.0150 (-0.94%)
     
  • NASDAQ

    15,993.71
    +72.14 (+0.45%)
     
  • VOLATILITY

    17.59
    +0.48 (+2.81%)
     
  • FTSE

    7,255.96
    -35.24 (-0.48%)
     
  • NIKKEI 225

    29,683.09
    +84.43 (+0.29%)
     
  • CAD/EUR

    0.6979
    +0.0004 (+0.06%)
     

Getting In Cheap On Ceapro Inc. (CVE:CZO) Is Unlikely

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Ceapro Inc.'s (CVE:CZO) price-to-earnings (or "P/E") ratio of 34.9x might make it look like a strong sell right now compared to the market in Canada, where around half of the companies have P/E ratios below 13x and even P/E's below 6x are quite common. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's so lofty.

With earnings growth that's exceedingly strong of late, Ceapro has been doing very well. The P/E is probably high because investors think this strong earnings growth will be enough to outperform the broader market in the near future. If not, then existing shareholders might be a little nervous about the viability of the share price.

View our latest analysis for Ceapro

pe
pe

Although there are no analyst estimates available for Ceapro, take a look at this free data-rich visualisation to see how the company stacks up on earnings, revenue and cash flow.

What Are Growth Metrics Telling Us About The High P/E?

The only time you'd be truly comfortable seeing a P/E as steep as Ceapro's is when the company's growth is on track to outshine the market decidedly.

Taking a look back first, we see that the company grew earnings per share by an impressive 97% last year. Still, EPS has barely risen at all from three years ago in total, which is not ideal. Therefore, it's fair to say that earnings growth has been inconsistent recently for the company.

Comparing that to the market, which is predicted to deliver 22% growth in the next 12 months, the company's momentum is weaker based on recent medium-term annualised earnings results.

In light of this, it's alarming that Ceapro's P/E sits above the majority of other companies. Apparently many investors in the company are way more bullish than recent times would indicate and aren't willing to let go of their stock at any price. There's a good chance existing shareholders are setting themselves up for future disappointment if the P/E falls to levels more in line with recent growth rates.

The Key Takeaway

Using the price-to-earnings ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.

We've established that Ceapro currently trades on a much higher than expected P/E since its recent three-year growth is lower than the wider market forecast. Right now we are increasingly uncomfortable with the high P/E as this earnings performance isn't likely to support such positive sentiment for long. Unless the recent medium-term conditions improve markedly, it's very challenging to accept these prices as being reasonable.

You need to take note of risks, for example - Ceapro has 3 warning signs (and 1 which is potentially serious) we think you should know about.

If these risks are making you reconsider your opinion on Ceapro, explore our interactive list of high quality stocks to get an idea of what else is out there.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting